551. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia.
- Author
-
Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, and Urushizaki I
- Subjects
- Animals, Cell Survival drug effects, Drug Administration Schedule, Mice, Neoplasms, Experimental drug therapy, Time Factors, Tumor Necrosis Factor-alpha administration & dosage, Tumor Necrosis Factor-alpha pharmacology, Hyperthermia, Induced, Neoplasms, Experimental therapy, Tumor Cells, Cultured drug effects, Tumor Necrosis Factor-alpha therapeutic use
- Abstract
A synergistic increase in the cytotoxic effects of recombinant human tumor necrosis factor (rH-TNF) and hyperthermia was demonstrated both in vitro and in vivo. The cytotoxicity of rH-TNF against L-M cells in incubation for 12 h at 38.5 and 40 degrees C based on the concentration necessary for 50% cytotoxicity was, respectively, 125 and more than 500 times as high as in similar incubation at 37 degrees C. As observed 18 days after implantation of Meth-A fibrosarcoma cells in mice, single i.v. administration of rH-TNF at 1000 units/mouse resulted in complete cures in five mice when performed in combination with hyperthermia (40 degrees C), whereas rH-TNF alone in the same dose resulted in 27.1% inhibition of tumor growth and hyperthermia alone had no appreciable effect on tumor growth. The i.v. administration of rH-TNF three times at 100 or 300 units/mouse together with hyperthermia (40 degrees C) resulted in 41.2 and 89.0% tumor growth inhibition, respectively; similar administration without hyperthermia appeared to have little or no appreciable effect on tumor growth. The results suggest that combination therapy including rH-TNF and hyperthermia may be of value in the treatment of malignancy in human patients.
- Published
- 1988